| Johnson, Matthew W |
| Active, not recruiting | 4 | 334 | Europe, Canada, RoW | 5-ASA Withdrawal | Alimentiv Inc., Academic Medical Organization of Southwestern Ontario | Crohn Disease, Remission | 06/26 | 06/26 | | |
NCT05452772: 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder |
|
|
| Recruiting | 2 | 66 | US | Psilocybin, Active Experimental Group, Niacin, Active Comparator Group | Johns Hopkins University, University of Alabama at Birmingham, New York University, National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder | 05/25 | 12/25 | | |
NCT05242029: Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use |
|
|
| Withdrawn | 2 | 92 | NA | Placebo, Psilocybin | Johns Hopkins University | Opioid Use Disorder | 02/24 | 12/24 | | |
| Active, not recruiting | 2 | 100 | US | Iron Dextran, Erythropoietin (EPO), EPO | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI) | Anemia, Critical Illness | 03/24 | 12/24 | | |
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) |
|
|
| Terminated | 2 | 6 | US | Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin | Aiwu Ruth He, MD, Georgetown University, Genentech, Inc. | Hepatocellular Carcinoma | 06/23 | 06/23 | | |
NCT04999644: Reduced Nicotine Cigarette Purchasing Decisions |
|
|
| Completed | 1 | 21 | US | Full Nicotine Cigarettes, Reduced Nicotine Cigarettes, Average Nicotine Expectancy, Very Low Nicotine Expectancy | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder | 03/23 | 03/23 | | |
NCT05562973: Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder |
|
|
| Withdrawn | 1 | 30 | NA | Psilocybin | Johns Hopkins University | Post-Traumatic Stress Disorder | 12/25 | 12/25 | | |
NCT05805046: Study of Avelle™ Negative Pressure Wound Therapy (NPWT) System |
|
|
| Withdrawn | N/A | 59 | US | Negative Pressure Wound Therapy System, Avelle™ Negative Pressure Wound Therapy System | ConvaTec Inc. | Surgical Wound, Recent, Surgical Wound Leak, Dehiscence Wound, Trauma-related Wound | 10/23 | 10/23 | | |
NCT01943994: Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study |
|
|
| Completed | N/A | 82 | US | Psilocybin-assisted treatment, O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine, Nicotine Replacement Therapy (NRT), Transdermal Nicotine Patch, Nicoderm CQ | Johns Hopkins University, Beckley Foundation, Heffter Research Institute | Nicotine Dependence | 05/23 | 11/23 | | |
NCT04927702: Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU) |
|
|
| Active, not recruiting | N/A | 170 | US | Synthetic Hybrid-Scale Fiber Matrix, Restrata, Standard of Care, Living Cellular Skin Substitute, Apligraf | Acera Surgical, Inc. | Diabetic Foot Ulcer, Venous Leg Ulcer | 07/24 | 08/24 | | |
| Completed | N/A | 31 | US | Smoking sessions | Johns Hopkins University, National Institute on Drug Abuse (NIDA) | Tobacco Smoking | 03/24 | 03/24 | | |
| Not yet recruiting | N/A | 50 | Europe | Data and Blood collection, MRI | University of Exeter, Royal Devon University Healthcare NHS Foundation Trust | Diabetes Mellitus, Monogenic Diabetes, Hyperinsulinism | 12/28 | 12/28 | | |
| Recruiting | N/A | 25 | US | Vim-Deep Brain Stimulation | University of Minnesota | Essential Tremor | 12/24 | 12/25 | | |
| Recruiting | N/A | 330 | US | Partial Colectomy, Medical Management | University of Washington, Patient-Centered Outcomes Research Institute | Diverticulitis | 05/25 | 01/26 | | |
Mavericks, NCT05758545: Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 320 | US | COMS One device, Concurrent Optical and Magnetic Stimulation, Sham device | Piomic Medical, NAMSA | Diabetic Foot Ulcer | 06/25 | 06/25 | | |
COMPLETE TAVR, NCT04634240: Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement |
|
|
| Recruiting | N/A | 4000 | Canada, US | Percutaneous Coronary Intervention (PCI) | University of British Columbia | Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis | 04/26 | 04/26 | | |
NCT05127915: US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism |
|
|
| Active, not recruiting | N/A | 854 | US | Adient absorbable filter + best practice VTE prophylaxis, best practice VTE prophylaxis | Adient Medical, Avania, ICON plc | Pulmonary Embolism | 05/26 | 12/26 | | |
NCT04343365: Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board |
|
|
| Recruiting | N/A | 35 | US | Evolutionary Tumor Board (ETB) | H. Lee Moffitt Cancer Center and Research Institute | Incurable Disease | 03/28 | 03/28 | | |
| Fishman, Marc J |
| Recruiting | 2 | 190 | US | CBOT + TAU, plant based essential oils, Sham + TAU | Evon Medics LLC, National Institute on Drug Abuse (NIDA), Howard University, Family and Medical Counseling Service, Inc, Maryland Treatment Centers @ ARTC, Clinics of Dr. Edwin Chapman, MD, PC @ MHDG | Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity | 11/22 | 12/22 | | |
PGB-LOF, NCT04218240: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal |
|
|
| Completed | 2 | 90 | US | Pregabalin 200 MG capsules, lyrica, Placebo oral tablet, Lofexidine 0.18Mg Tab, lucemyra | University of Pennsylvania | Opioid Withdrawal | 03/23 | 03/23 | | |
EDITOR, NCT06434818: Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders |
|
|
| Recruiting | 2 | 300 | US | EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), EDITOR plus Treatment-As-Usual (TAU), CBOT with olfactory stimulants & OFC tasks, CBOT active plus TAU, CBOT Sham, CBOT passive plus TAU | Evon Medics LLC, Howard University, Maryland Treatment Center, Clinics of Dr. Edwin Chapman, MD, PC @ MHDG, National Institute on Drug Abuse (NIDA) | Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence | 03/25 | 06/25 | | |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) |
|
|
| Recruiting | 2 | 2190 | US | SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD | NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid Use Disorder (OUD) | 07/26 | 12/26 | | |
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal |
|
|
| Recruiting | 2 | 150 | US | LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin | University of Pennsylvania | Opiate Withdrawal Syndrome, Opioid Use | 08/26 | 08/26 | | |
| Recruiting | N/A | 100 | US | Written Exposure Therapy, Treatment as Usual | Potomac Health Foundations, University of Maryland, Baltimore County | Posttraumatic Stress Disorder, Substance Use Disorders | 06/24 | 12/24 | | |
| Completed | N/A | 45 | US | MAT-PLUS "Helping Hands" | Potomac Health Foundations | Opioid Dependence, Opioid-Related Disorders | 06/23 | 06/23 | | |
| Recruiting | N/A | 150 | US | Youth Opioid Recovery Support (YORS) | Potomac Health Foundations, National Institutes of Health (NIH), Friends Research Institute, Inc., National Center for Complementary and Integrative Health (NCCIH), National Institute on Drug Abuse (NIDA) | Opioid-use Disorder, Medication Adherence | 08/24 | 08/24 | | |
NCT05616949: Peer Recovery Support Services for Individuals in Recovery Residences on MOUD |
|
|
| Recruiting | N/A | 50 | US | Treatment as Usual (TAU) (Arm 1), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2) | Potomac Health Foundations, National Institute of Drug Abuse, National Institutes of Health (NIH) | Opioid Use Disorder, Substance Use Disorder | 01/25 | 09/25 | | |
| Recruiting | N/A | 1200 | Canada, US | | Indivior Inc. | Opioid Use Disorder | 08/27 | 08/27 | | |
| Wenzel, Kevin |
COMBO, NCT05011266: Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder |
|
|
| Recruiting | 2/3 | 180 | US | Buprenorphine/naloxone, Zubsolv, Placebo, PBO | New York State Psychiatric Institute, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 06/26 | 06/26 | | |
| Recruiting | 2 | 190 | US | CBOT + TAU, plant based essential oils, Sham + TAU | Evon Medics LLC, National Institute on Drug Abuse (NIDA), Howard University, Family and Medical Counseling Service, Inc, Maryland Treatment Centers @ ARTC, Clinics of Dr. Edwin Chapman, MD, PC @ MHDG | Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving, Negative Affectivity | 11/22 | 12/22 | | |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) |
|
|
| Recruiting | 2 | 2190 | US | SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD | NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC | Opioid Use Disorder (OUD) | 07/26 | 12/26 | | |
UH3, NCT05995535: Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal |
|
|
| Recruiting | 2 | 150 | US | LFX/PGB, Lucemyra, lyrica, LFX/PLA-PGB, placebo pregabalin | University of Pennsylvania | Opiate Withdrawal Syndrome, Opioid Use | 08/26 | 08/26 | | |
| Recruiting | N/A | 100 | US | Written Exposure Therapy, Treatment as Usual | Potomac Health Foundations, University of Maryland, Baltimore County | Posttraumatic Stress Disorder, Substance Use Disorders | 06/24 | 12/24 | | |
| Completed | N/A | 45 | US | MAT-PLUS "Helping Hands" | Potomac Health Foundations | Opioid Dependence, Opioid-Related Disorders | 06/23 | 06/23 | | |
| Recruiting | N/A | 150 | US | Youth Opioid Recovery Support (YORS) | Potomac Health Foundations, National Institutes of Health (NIH), Friends Research Institute, Inc., National Center for Complementary and Integrative Health (NCCIH), National Institute on Drug Abuse (NIDA) | Opioid-use Disorder, Medication Adherence | 08/24 | 08/24 | | |
NCT05616949: Peer Recovery Support Services for Individuals in Recovery Residences on MOUD |
|
|
| Recruiting | N/A | 50 | US | Treatment as Usual (TAU) (Arm 1), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2) | Potomac Health Foundations, National Institute of Drug Abuse, National Institutes of Health (NIH) | Opioid Use Disorder, Substance Use Disorder | 01/25 | 09/25 | | |
| MacNicoll, Sandra |
CURB-2, NCT05262270: Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder |
|
|
| Recruiting | 2 | 426 | US | Extended-Release Naltrexone, XR-NTX, Extended Release Buprenorphine, XR-BUP, Placebo (PLB) Injectable matched to XR-NTX, Injectable matching (to XR-NTX) placebo, Placebo (PLB) Injectable matched to XR-BUP, Injectable matching (to XR-BUP) placebo | University of Texas Southwestern Medical Center, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 03/25 | 09/26 | | |
